News Roche doubles down on BTK with $2.3bn Nurix deal Roche is paying $700m upfront for rights to bexobrutideg, a BTK degrader that it says has potential across oncology, immunology, and neurology.
News Incyte gobbles up Star's Vega haematology unit in $2bn deal Incyte has agreed to buy Star Therapeutics' Vega subsidiary for $1.25bn upfront, adding a late-stage drug candidate for bleeding disorder VWD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.